A phase 2 RCT evaluated progression of prostate-specific antigen and urinary symptoms in men with low-risk prostate cancer who were administered phytochemical-rich food and Lactobacillus probiotic ...
Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback